Annual report pursuant to Section 13 and 15(d)

License, Clinical Trial and Sponsored Research Agreements (Tables)

v3.21.1
License, Clinical Trial and Sponsored Research Agreements (Tables)
12 Months Ended
Dec. 31, 2020
License Agreements [Member]  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of License, Clinical Trial and Sponsored Research Agreements

For the years ended December 31, 2020 and 2019, the Company recorded the following expense in research and development for licenses acquired:

For the year ended December 31, 

($ in thousands)

    

2020

    

2019

City of Hope National Medical Center

CD123

$

334

$

250

CS1

200

200

IL13Rα2

333

Spacer

333

PSCA

200

200

HER2

500

CSL Behring (Calimmune)

170

200

UCLA

300

Fred Hutchinson Cancer Research Center - CD20

300

Nationwide Children's Hospital - C134

200

SIRION Biotech LentiBOOSTTM

117

Fortress PIK Dividend

7,577

4,923

Total

$

10,064

$

6,273

Sponsored Research and Clinical Trial Agreements [Member]  
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]  
Schedule of License, Clinical Trial and Sponsored Research Agreements

For the year ended December 31, 2020 and 2019, the Company recorded the following expense in research and development for sponsored research and clinical trial agreements:

For the year ended December 31, 

($ in thousands)

    

2020

    

2019

City of Hope National Medical Center

500

2,000

CD123

433

1,202

IL13Rα2

530

876

CS1

885

HER2

1,519

PSCA

204

Manufacturing

457

Fred Hutchinson Cancer Research Center - CD20

1,804

762

St. Jude Children's Research Hospital - XSCID

1,842

777

Beth Israel Deaconess Medical Center - CRISPR

69

Total

7,717

6,143